Myriad Genetics Inc (MYGN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Myriad Genetics Inc (MYGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10094
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD30 Million in Venture Financing Round 15
Assurex Health Raises USD30 Million in Venture Financing 17
AssureRx Health Raises USD7 Million in Venture Financing 18
RainDance Technologies Raises US$20 Million In Series E Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
AssureRx Health Raises US$12.5 Million In Series C Financing 24
Counsyl Secures USD34 Million in Series B Round of Funding 26
Assurex Health Secures USD8 Million in Venture Funding Round 27
Private Equity 28
Perceptive Advisors Invests USD80 Million in Counsyl 28
Partnerships 29
Myriad Genetics and Pfizer Enter into Agreement 29
Myriad Genetics Enters into Development Agreement with Beigene 30
Myriad Enters into Agreement with Sanofi 31
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33
Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34
Myriad Genetics Expands Research Agreement with AbbVie 35
Acquisition 36
Myriad Genetics Acquires Assurex Health for USD351.6 Million 36
Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38
Myriad Genetics Inc – Key Competitors 39
Myriad Genetics Inc – Key Employees 40
Myriad Genetics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 43
May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 46
Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 48
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 50
Aug 08, 2017: Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results 51
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 52
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 54
Legal and Regulatory 56
Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against  Myriad Genetics, Inc. 56
Government and Public Interest 57
Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD30 Million in Venture Financing Round 15
Assurex Health Raises USD30 Million in Venture Financing 17
AssureRx Health Raises USD7 Million in Venture Financing 18
RainDance Technologies Raises US$20 Million In Series E Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
AssureRx Health Raises US$12.5 Million In Series C Financing 24
Counsyl Secures USD34 Million in Series B Round of Funding 26
Assurex Health Secures USD8 Million in Venture Funding Round 27
Perceptive Advisors Invests USD80 Million in Counsyl 28
Myriad Genetics and Pfizer Enter into Agreement 29
Myriad Genetics Enters into Development Agreement with Beigene 30
Myriad Enters into Agreement with Sanofi 31
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33
Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34
Myriad Genetics Expands Research Agreement with AbbVie 35
Myriad Genetics Acquires Assurex Health for USD351.6 Million 36
Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38
Myriad Genetics Inc, Key Competitors 39
Myriad Genetics Inc, Key Employees 40
Myriad Genetics Inc, Subsidiaries 41

List of Figures
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Myriad Genetics Inc (MYGN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Miromatrix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …
  • Peak Resources Ltd. (PEK):企業の財務・戦略的SWOT分析
    Peak Resources Ltd. (PEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • DermTech Inc-医療機器分野:企業M&A・提携分析
    Summary DermTech Inc (DermTech) is a precision medicine developer that offers molecular tests. The company’s products include adhesive skin sample collection kit and pigmented lesion assay. Its EGIR platform technology is applicable in non-invasive, genomic-based disease detection, theranostics, pha …
  • Ridley Corporation Ltd:企業の戦略・SWOT・財務分析
    Ridley Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Ridley Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Columbia Power Corporation:企業の戦略的SWOT分析
    Columbia Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Ems-Chemie Holding AG (EMSN):企業の財務・戦略的SWOT分析
    Summary Ems-Chemie Holding AG (Ems-Chemie), a subsidiary of Emesta Holding AG, is a chemical company. The company manufactures and markets high performance polymers and specialty chemicals. Its products include bonding products, polyamides, damping systems, sealants, and coating products. Ems-Chemie …
  • ALLETE Inc (ALE):電力:M&Aディール及び事業提携情報
    Summary ALLETE Inc (ALLETE) is an energy company. It has interests in mining facilities; electricity generation, transmission, and distribution assets; and water management businesses. The company generates electricity using coal, natural gas, biomass, hydro, wind, and solar; and procures energy thr …
  • Tourmaline Oil Corp.:企業のM&A・事業提携・投資動向
    Tourmaline Oil Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tourmaline Oil Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Samsung Engineering Co Ltd (028050):企業の財務・戦略的SWOT分析
    Samsung Engineering Co Ltd (028050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Arsenal Medical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Arsenal Medical Inc (Arsenal) is a platform technology company that develops novel therapeutic polymer based foams. The company’s products include in-situ forming materials, in-situ forming polymeric foam and in-situ curing elastomeric polymer material. It offers in-situ forming materials to …
  • TDC AS (TDC):企業の財務・戦略的SWOT分析
    TDC AS (TDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Mitsui E&S Holdings Co., Ltd. (7003):企業の財務・戦略的SWOT分析
    Mitsui E&S Holdings Co., Ltd. (7003) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • University of Cambridge:企業のM&A・事業提携・投資動向
    University of Cambridge - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Cambridge Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Guangzhou Boji Medical & Biotechnological Co Ltd (300404):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Boji Medical & Biotechnological Co Ltd (BOJI) is a contract research organization. The organization provides services including regulatory affairs, preclinical research, clinical trials I-IV, PMS, clinical trial for medical devices, post marketing studies (PMS), data management and …
  • Seair Inc:企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Renova Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Renova Therapeutics Inc (Renova) is a drug development company that focuses on the development of peptide infusion therapies and gene therapy treatments for cardiovascular and metabolic diseases. The company’s pipeline products include RT-100, RT-200, RT-110, RT-400, RT-210 and RT-300. Its R …
  • Protokinetix Inc (PKTX):企業の財務・戦略的SWOT分析
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • Animal Health International Inc:企業の戦略的SWOT分析
    Animal Health International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆